PTC Therapeutics (PTCT) Projected to Post Quarterly Earnings on Thursday

PTC Therapeutics (NASDAQ:PTCT) is expected to be releasing its Q4 2025 results after the market closes on Thursday, February 19th. Analysts expect the company to announce earnings of ($0.37) per share and revenue of $281.4530 million for the quarter. Interested persons are encouraged to explore the company’s upcoming Q4 2025 earning overview page for the latest details on the call scheduled for Thursday, February 19, 2026 at 4:30 PM ET.

PTC Therapeutics Stock Performance

Shares of NASDAQ:PTCT opened at $70.92 on Thursday. The company’s fifty day moving average is $75.76 and its two-hundred day moving average is $67.07. PTC Therapeutics has a 1-year low of $35.95 and a 1-year high of $87.50. The stock has a market capitalization of $5.69 billion, a price-to-earnings ratio of 8.29 and a beta of 0.48.

Insiders Place Their Bets

In other PTC Therapeutics news, Director Allan Steven Jacobson sold 14,199 shares of the company’s stock in a transaction dated Tuesday, November 25th. The shares were sold at an average price of $83.55, for a total transaction of $1,186,326.45. Following the completion of the sale, the director directly owned 17,451 shares in the company, valued at $1,458,031.05. This represents a 44.86% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Eric Pauwels sold 40,290 shares of the company’s stock in a transaction on Wednesday, December 17th. The shares were sold at an average price of $75.43, for a total value of $3,039,074.70. Following the completion of the transaction, the insider owned 70,373 shares of the company’s stock, valued at $5,308,235.39. The trade was a 36.41% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold 283,683 shares of company stock worth $22,504,021 in the last three months. 5.50% of the stock is owned by insiders.

Hedge Funds Weigh In On PTC Therapeutics

Several large investors have recently bought and sold shares of PTCT. IFP Advisors Inc increased its position in shares of PTC Therapeutics by 68.1% in the 3rd quarter. IFP Advisors Inc now owns 765 shares of the biopharmaceutical company’s stock valued at $47,000 after buying an additional 310 shares in the last quarter. Mariner LLC raised its stake in shares of PTC Therapeutics by 5.1% during the 3rd quarter. Mariner LLC now owns 8,745 shares of the biopharmaceutical company’s stock worth $537,000 after purchasing an additional 426 shares in the last quarter. Comerica Bank increased its stake in shares of PTC Therapeutics by 868.5% during the 3rd quarter. Comerica Bank now owns 523 shares of the biopharmaceutical company’s stock worth $32,000 after purchasing an additional 469 shares during the last quarter. EverSource Wealth Advisors LLC raised its holdings in shares of PTC Therapeutics by 247.4% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 1,143 shares of the biopharmaceutical company’s stock valued at $56,000 after purchasing an additional 814 shares during the period. Finally, Cerity Partners LLC increased its holdings in shares of PTC Therapeutics by 9.4% during the 4th quarter. Cerity Partners LLC now owns 11,204 shares of the biopharmaceutical company’s stock worth $851,000 after acquiring an additional 964 shares during the last quarter.

Analyst Upgrades and Downgrades

A number of research analysts have issued reports on the company. Jefferies Financial Group boosted their price target on PTC Therapeutics from $63.00 to $77.00 and gave the stock a “buy” rating in a research report on Tuesday, October 28th. Weiss Ratings reissued a “hold (c)” rating on shares of PTC Therapeutics in a report on Monday, December 29th. The Goldman Sachs Group lifted their price objective on shares of PTC Therapeutics from $44.00 to $50.00 and gave the stock a “sell” rating in a research note on Wednesday, November 5th. Wall Street Zen upgraded shares of PTC Therapeutics from a “hold” rating to a “buy” rating in a report on Saturday, January 3rd. Finally, Royal Bank Of Canada cut shares of PTC Therapeutics from an “outperform” rating to a “sector perform” rating and raised their target price for the stock from $82.00 to $91.00 in a report on Monday, December 1st. Ten investment analysts have rated the stock with a Buy rating, five have issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, PTC Therapeutics has an average rating of “Moderate Buy” and a consensus price target of $80.67.

About PTC Therapeutics

PTC Therapeutics, Inc is a biopharmaceutical company focused on the discovery, development and commercialization of small molecule and biologic therapies for the treatment of rare genetic disorders. Since its founding in 1998, PTC has dedicated its efforts to addressing high unmet medical needs by targeting underlying genetic causes of disease. The company’s research platform emphasizes mechanisms such as nonsense suppression and RNA modulation, enabling the development of novel treatments for conditions with limited therapeutic options.

Among PTC’s approved products is Translarna (ataluren), a first-in-class therapy designed to treat nonsense mutation Duchenne muscular dystrophy in select markets.